Xane Iphase ds8201a

Iphase ds8201a

Danasîna kurt:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Têkilî Naha Têxe selikê

Kîtekîteya Hilbera

Tags Product

Danasîna Hilbera DS - 8201A, di heman demê de wekî Trastuzumab Deruxtecan (T - DXD), antîdîfek e, antibo ye - Conjugate Drug Ew her2 a2 - Targetkirina antikody monoclonal (mîna Trastuzumab) bi topoisomerase ku ez pêgirtin (DeruxeCan) wekî payloada cytotoxic. Dermanê kemoterapiyê rasterast ji hucreyên kanserê re vedihewîne

Liq:
Catyepsin
Jimara heyber.:
015200.02
Mezinahiya yekîneyê:
200L, 2mg / ML
Desmal:
N / A
Cureyên:
N / A
Condert û veguhastina hilanînê:
Hilînin li - 70 ° C. Berfê hişk radibe.